Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 187

1.

Management of pulmonary toxicity associated with immune checkpoint inhibitors.

Delaunay M, Prévot G, Collot S, Guilleminault L, Didier A, Mazières J.

Eur Respir Rev. 2019 Nov 6;28(154). pii: 190012. doi: 10.1183/16000617.0012-2019. Print 2019 Dec 31. Review.

2.

Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma.

Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A.

J Clin Invest. 2019 Oct 31. pii: 126896. doi: 10.1172/JCI126896. [Epub ahead of print]

3.

[Immune-related adverse events after immune checkpoints inhibitors in 2019: An update].

Comont T, Belliere J, Sibaud V, Alric L, Meyer N, Mazières J, Caron P, Acket B, Michot JM, Beyne-Rauzy O, Lambotte O.

Rev Med Interne. 2019 Oct 24. pii: S0248-8663(19)30656-3. doi: 10.1016/j.revmed.2019.09.005. [Epub ahead of print] French.

PMID:
31668882
4.

Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.

Alcala N, Mangiante L, Le-Stang N, Gustafson CE, Boyault S, Damiola F, Alcala K, Brevet M, Thivolet-Bejui F, Blanc-Fournier C, Le Rochais JP, Planchard G, Rousseau N, Damotte D, Pairon JC, Copin MC, Scherpereel A, Wasielewski E, Wicquart L, Lacomme S, Vignaud JM, Ancelin G, Girard C, Sagan C, Bonnetaud C, Hofman V, Hofman P, Mouroux J, Thomas de Montpreville V, Clermont-Taranchon E, Mazieres J, Rouquette I, Begueret H, Blay JY, Lantuejoul S, Bueno R, Caux C, Girard N, McKay JD, Foll M, Galateau-Salle F, Fernandez-Cuesta L.

EBioMedicine. 2019 Oct;48:191-202. doi: 10.1016/j.ebiom.2019.09.003. Epub 2019 Oct 21.

5.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

Moro-Sibilot D, Cozic N, Pérol M, Mazières J, Otto J, Souquet PJ, Bahleda R, Wislez M, Zalcman G, De Guibert S, Barlési F, Mennecier B, Monnet I, Sabatier R, Bota S, Dubos C, Verriele V, Haddad V, Ferretti G, Cortot A, De Fraipont F, Jimenez M, Hoog-Labouret N, Vassal G.

Ann Oncol. 2019 Oct 4. pii: mdz407. doi: 10.1093/annonc/mdz407. [Epub ahead of print]

PMID:
31584608
6.

Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer.

Guibert N, Jones G, Beeler JF, Plagnol V, Morris C, Mourlanette J, Delaunay M, Keller L, Rouquette I, Favre G, Pradines A, Mazieres J.

Lung Cancer. 2019 Nov;137:1-6. doi: 10.1016/j.lungcan.2019.09.005. Epub 2019 Sep 6.

PMID:
31518912
7.

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC.

ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.

8.

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.

Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.

Clin Lung Cancer. 2019 Sep;20(5):e564-e575. doi: 10.1016/j.cllc.2019.04.010. Epub 2019 May 13.

PMID:
31279641
9.

Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.

Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Duchemann B, Cousin S, le Pechoux C, Botticella A, De Ruysscher D, Dingemans AC, Besse B.

Eur J Cancer. 2019 Jul;116:182-189. doi: 10.1016/j.ejca.2019.05.019. Epub 2019 Jun 13.

PMID:
31203193
10.

[Management of non-small cell lung cancer patients harboring activating mutations and CNS progression].

Rouviere D, Veillon R, Chaltiel L, Simonneau Y, Filleron T, Milia J, Guibert N, Melloni B, Raherison C, Didier A, Mazieres J.

Rev Mal Respir. 2019 May;36(5):583-590. doi: 10.1016/j.rmr.2019.04.003. Epub 2019 Jun 13. French.

PMID:
31202602
11.

Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Léna H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V; French Cooperative Thoracic Intergroup (IFCT).

Clin Cancer Res. 2019 Oct 1;25(19):5759-5765. doi: 10.1158/1078-0432.CCR-18-2860. Epub 2019 Jun 7.

PMID:
31175096
12.

When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?

Mhanna L, Guibert N, Milia J, Mazieres J.

Curr Treat Options Oncol. 2019 Jun 6;20(7):60. doi: 10.1007/s11864-019-0652-3. Review.

13.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazières J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van Den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 May 24. pii: mdz167. doi: 10.1093/annonc/mdz167. [Epub ahead of print]

PMID:
31125062
14.

Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients.

Campredon P, Mouly C, Lusque A, Bigay-Game L, Bousquet E, Mazières J, Caron P.

Presse Med. 2019 Apr;48(4):e199-e207. doi: 10.1016/j.lpm.2018.10.019. Epub 2019 Apr 17.

PMID:
31005502
15.

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients.

Hofman V, Rouquette I, Long-Mira E, Piton N, Chamorey E, Heeke S, Vignaud JM, Yguel C, Mazières J, Lepage AL, Bibeau F, Begueret H, Lassalle S, Lalvée S, Zahaf K, Benzaquen J, Poudenx M, Marquette CH, Sabourin JC, Ilié M, Hofman P.

J Thorac Oncol. 2019 Jul;14(7):1204-1212. doi: 10.1016/j.jtho.2019.03.024. Epub 2019 Apr 15.

PMID:
30999109
16.

Treatment of complex airway stenoses using patient-specific 3D-engineered stents: a proof-of-concept study.

Guibert N, Didier A, Moreno B, Lepage B, Leyx P, Plat G, Mhanna L, Murris M, Mazières J, Hermant C.

Thorax. 2019 Aug;74(8):810-813. doi: 10.1136/thoraxjnl-2018-212732. Epub 2019 Apr 3.

PMID:
30944151
17.

Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs.

Vendrell JA, Mazieres J, Senal R, Rouquette I, Quantin X, Pujol JL, Roch B, Bouidioua A, Godreuil S, Coyaud E, Brousset P, Solassol J.

Clin Cancer Res. 2019 Jul 15;25(14):4280-4289. doi: 10.1158/1078-0432.CCR-18-2683. Epub 2019 Apr 1.

PMID:
30936123
18.

Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner.

Bianco JN, Bergoglio V, Lin YL, Pillaire MJ, Schmitz AL, Gilhodes J, Lusque A, Mazières J, Lacroix-Triki M, Roumeliotis TI, Choudhary J, Moreaux J, Hoffmann JS, Tourrière H, Pasero P.

Nat Commun. 2019 Feb 22;10(1):910. doi: 10.1038/s41467-019-08886-8.

19.

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.

Hendriks LEL, Henon C, Auclin E, Mezquita L, Ferrara R, Audigier-Valette C, Mazieres J, Lefebvre C, Rabeau A, Le Moulec S, Cousin S, Duchemann B, le Pechoux C, Botticella A, Ammari S, Gazzah A, Caramella C, Adam J, Lechapt E, Planchard D, De Ruysscher D, Dingemans AM, Besse B.

J Thorac Oncol. 2019 Jul;14(7):1244-1254. doi: 10.1016/j.jtho.2019.02.009. Epub 2019 Feb 16.

PMID:
30780002
20.

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.

Maille E, Brosseau S, Hanoux V, Creveuil C, Danel C, Bergot E, Scherpereel A, Mazières J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Langlais A, Morin F, Levallet G, Zalcman G.

Br J Cancer. 2019 Feb;120(4):387-397. doi: 10.1038/s41416-019-0379-8. Epub 2019 Feb 11.

PMID:
30739911
21.

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).

Jeanson A, Tomasini P, Souquet-Bressand M, Brandone N, Boucekine M, Grangeon M, Chaleat S, Khobta N, Milia J, Mhanna L, Greillier L, Biemar J, Nanni I, Ouafik L, Garcia S, Mazières J, Barlesi F, Mascaux C.

J Thorac Oncol. 2019 Jun;14(6):1095-1101. doi: 10.1016/j.jtho.2019.01.011. Epub 2019 Feb 6.

PMID:
30738221
22.

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study.

Lai WV, Lebas L, Barnes TA, Milia J, Ni A, Gautschi O, Peters S, Ferrara R, Plodkowski AJ, Kavanagh J, Sabari JK, Clarke SJ, Pavlakis N, Drilon A, Rudin CM, Arcila ME, Leighl NB, Shepherd FA, Kris MG, Mazières J, Li BT.

Eur J Cancer. 2019 Mar;109:28-35. doi: 10.1016/j.ejca.2018.11.030. Epub 2019 Jan 24.

PMID:
30685684
23.

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.

Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup.

Lancet Oncol. 2019 Feb;20(2):239-253. doi: 10.1016/S1470-2045(18)30765-4. Epub 2019 Jan 16. Erratum in: Lancet Oncol. 2019 Mar;20(3):e132.

PMID:
30660609
24.

Thoracic Air-Leak Syndrome Complicating Allogeneic Hematopoietic Stem-Cell Transplantation.

Boghanim T, Murris M, Lamon T, Huynh A, Mazières J, Marquette CH, Didier A.

Lung. 2019 Feb;197(1):101-103. doi: 10.1007/s00408-018-0173-z. Epub 2018 Oct 29.

PMID:
30374588
25.

Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators.

N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.

26.

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France.

Bigay-Gamé L, Bota S, Greillier L, Monnet I, Madroszyk A, Corre R, Mastroianni B, Falchero L, Mazières J, Colineaux H, Lepage B, Chouaid C; GFPC Investigators.

Oncology. 2018;95(6):337-343. doi: 10.1159/000489784. Epub 2018 Oct 2.

PMID:
30278447
27.

[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].

Faviez G, Bousquet E, Rabeau A, Rouquette I, Collot S, Goumarre C, Meyer N, Prevot G, Mazieres J.

Rev Mal Respir. 2018 Nov;35(9):963-967. doi: 10.1016/j.rmr.2018.08.003. Epub 2018 Sep 13. French.

PMID:
30220489
28.

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.

Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L.

J Thorac Oncol. 2018 Dec;13(12):1906-1918. doi: 10.1016/j.jtho.2018.08.2027. Epub 2018 Sep 11.

PMID:
30217492
29.

A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics.

Ferrer L, Giaj Levra M, Brevet M, Antoine M, Mazieres J, Rossi G, Chiari R, Westeel V, Poudenx M, Letreut J, Gervais R, Osman G, Girard N, Toffart AC, Novello S, Moro-Sibilot D.

J Thorac Oncol. 2019 Jan;14(1):130-134. doi: 10.1016/j.jtho.2018.08.2028. Epub 2018 Sep 11.

PMID:
30217489
30.

[Toxicity of immune checkpoints inhibitors].

Delaunay M, Caron P, Sibaud V, Godillot C, Collot S, Milia J, Prévot G, Mazières J.

Rev Mal Respir. 2018 Dec;35(10):1028-1038. doi: 10.1016/j.rmr.2017.08.006. Epub 2018 Sep 10. Review. French.

PMID:
30213624
31.

Cytoplasmic p27Kip1 promotes tumorigenesis via suppression of RhoB activity.

Calvayrac O, Nowosad A, Cabantous S, Lin LP, Figarol S, Jeannot P, Serres MP, Callot C, Perchey RT, Creff J, Taranchon-Clermont E, Rouquette I, Favre G, Pradines A, Manenti S, Mazieres J, Lee H, Besson A.

J Pathol. 2019 Jan;247(1):60-71. doi: 10.1002/path.5167. Epub 2018 Dec 11.

PMID:
30206932
32.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676.

33.

c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.

Mignard X, Ruppert AM, Antoine M, Vasseur J, Girard N, Mazières J, Moro-Sibilot D, Fallet V, Rabbe N, Thivolet-Bejui F, Rouquette I, Lantuejoul S, Cortot A, Saffroy R, Cadranel J, Lemoine A, Wislez M.

J Thorac Oncol. 2018 Dec;13(12):1962-1967. doi: 10.1016/j.jtho.2018.08.008. Epub 2018 Aug 24.

34.

Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.

Merveilleux du Vignaux C, Dansin E, Mhanna L, Greillier L, Pichon E, Kerjouan M, Clément-Duchêne C, Mennecier B, Westeel V, Robert M, Quantin X, Zalcman G, Thiberville L, Lena H, Molina T, Calcagno F, Fournel P, Mazières J, Besse B, Girard N.

J Thorac Oncol. 2018 Nov;13(11):1762-1770. doi: 10.1016/j.jtho.2018.08.005. Epub 2018 Aug 21.

35.

Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit.

Puisset F, Bigay-Game L, Paludetto MN, Martel A, Perriat S, Rabeau A, Canonge JM, Mazieres J.

Support Care Cancer. 2019 May;27(5):1679-1686. doi: 10.1007/s00520-018-4415-7. Epub 2018 Aug 17.

PMID:
30120556
36.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

37.

Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.

Falk AT, Yazbeck N, Guibert N, Chamorey E, Paquet A, Ribeyre L, Bence C, Zahaf K, Leroy S, Marquette CH, Cohen C, Mograbi B, Mazières J, Hofman V, Brest P, Hofman P, Ilié M.

Lung Cancer. 2018 Jul;121:70-75. doi: 10.1016/j.lungcan.2018.05.009. Epub 2018 May 26.

PMID:
29858030
38.

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.

Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, Mourlanette J, Gouin S, Dormoy I, Favre G, Mazieres J, Pradines A.

Lung Cancer. 2018 Jun;120:108-112. doi: 10.1016/j.lungcan.2018.04.001. Epub 2018 Apr 3.

PMID:
29748004
39.

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.

Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J.

Ann Oncol. 2018 Jun 1;29(6):1409-1416. doi: 10.1093/annonc/mdy121.

40.

Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment.

Campredon P, Imbert P, Mouly C, Grunenwald S, Mazières J, Caron P.

Eur Thyroid J. 2018 Mar;7(2):84-87. doi: 10.1159/000485742. Epub 2018 Jan 4.

41.

Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study.

Loubière S, Drezet A, Beau-Faller M, Moro-Sibilot D, Friard S, Wislez M, Blons H, Daniel C, Westeel V, Madroszyk A, Léna H, Merle P, Mazières J, Zalcman G, Lacave R, Antoine M, Morin F, Missy P, Barlesi F, Auquier P, Cadranel J; French Cooperative Thoracic Intergroup (IFCT).

Eur Respir J. 2018 Mar 15;51(3). pii: 1701467. doi: 10.1183/13993003.01467-2017. Print 2018 Mar.

42.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
43.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients.

Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazieres J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenegre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B.

ERJ Open Res. 2018 Feb 13;4(1). pii: 00058-2017. doi: 10.1183/23120541.00058-2017. eCollection 2018 Jan.

44.

Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.

Costantini A, Grynovska M, Lucibello F, Moisés J, Pagès F, Tsao MS, Shepherd FA, Bouchaab H, Garassino M, Aerts JGJV, Mazières J, Mondini M, Berghmans T, Meert AP, Cadranel J.

Eur Respir J. 2018 Feb 14;51(2). pii: 1702072. doi: 10.1183/13993003.02072-2017. Print 2018 Feb.

45.

Integration of 3D printing and additive manufacturing in the interventional pulmonologist's toolbox.

Guibert N, Mhanna L, Didier A, Moreno B, Leyx P, Plat G, Mazieres J, Hermant C.

Respir Med. 2018 Jan;134:139-142. doi: 10.1016/j.rmed.2017.11.019. Epub 2017 Dec 2. Review.

PMID:
29413501
46.

[The Ras-related GTPase RhoB, a relevant actor in the adaptive resistance to EGFR tyrosine kinase inhibitors in lung cancers].

Calvayrac O, Pradines A, Mazières J, Favre G.

Med Sci (Paris). 2018 Jan;34(1):12-14. doi: 10.1051/medsci/20183401003. Epub 2018 Jan 31. French. No abstract available.

47.

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L, Audigier-Valette C, Felip E, Zerón-Medina J, Garrido P, Brosseau S, Zalcman G, Mazieres J, Caramela C, Lahmar J, Adam J, Chaput N, Soria JC, Besse B.

JAMA Oncol. 2018 Mar 1;4(3):351-357. doi: 10.1001/jamaoncol.2017.4771.

48.

Concerns About Lung Cancer Among Prisoners.

Renault L, Perrot E, Pradat E, Bartoli C, Greillier L, Remacle-Bonnet A, Telmon N, Mazières J, Molinier L, Couraud S.

Lung. 2018 Feb;196(1):115-124. doi: 10.1007/s00408-017-0066-6. Epub 2018 Jan 3.

PMID:
29299681
49.

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.

Baldacci S, Mazieres J, Tomasini P, Girard N, Guisier F, Audigier-Valette C, Monnet I, Wislez M, Pérol M, Dô P, Dansin E, Leduc C, Giroux Leprieur E, Moro-Sibilot D, Tulasne D, Kherrouche Z, Labreuche J, Cortot AB.

Oncotarget. 2017 Oct 9;8(62):105103-105114. doi: 10.18632/oncotarget.21707. eCollection 2017 Dec 1.

50.

Circulating tumour cells as a potential screening tool for lung cancer (the AIR study): protocol of a prospective multicentre cohort study in France.

Leroy S, Benzaquen J, Mazzetta A, Marchand-Adam S, Padovani B, Israel-Biet D, Pison C, Chanez P, Cadranel J, Mazières J, Jounieaux V, Cohen C, Hofman V, Ilie M, Hofman P, Marquette CH; AIR Project Study Group.

BMJ Open. 2017 Dec 26;7(12):e018884. doi: 10.1136/bmjopen-2017-018884.

Supplemental Content

Loading ...
Support Center